Targeted Therapies

Our pipeline contains highly targeted mechanisms of action with the potential to become first-in-class medications.


Clinical Stage Pipeline

We are rapidly advancing a rich pipeline of novel targeted therapeutics with broad clinical utility across the areas of Immunology and Rare Genetic Diseases.

Differentiating Attributes of Our Programs

  • Novel mechanisms offering potential as first-in-class medications
  • First available therapy and/or substantial improvement over existing therapies for serious diseases
  • Targeted mechanisms of action with the potential for a favorable benefit-risk profile
  • Candidates for accelerated clinical development and regulatory pathways
  • Identified biomarkers and/or published clinical proof of concept increase the probability of regulatory approval
  • Associated biomarkers offer the potential for better patient identification and higher response rates